The Conversation Brazil’s president rejects COVID-19 vaccine, undermining a century of progress toward universal inoculation The world is eagerly awaiting the release of several COVID-19 vaccines, but Brazilian President Jair Bolsonaro is not. “I’m not going to take it. It’s my right,” he said in a Nov. 26 social media broadcast. Bolsonaro, who came down with COVID-19 in July, has also criticized face masks. He and his more faithful supporters oppose any suggestion of mandatory… Source link
Read More »Moderna hits $58B as it files for COVID-19 vaccine emergency use
TipRanks Billionaire Israel Englander Pours Money Into 2 “Strong Buy” Stocks Following the wild ride that was 2020, where does the market go from here? Major strides have been made in the COVID-19 vaccine race, yet the near-term picture remains unclear, blurred by the virus’ resurgence and the stimulus stalemate on Capitol Hill.In times like these, the investing greats can serve as a source of inspiration, namely billionaire Israel “Izzy” Englander.Who exactly is Englander? The… Source link
Read More »Moderna says its vaccine is 94.5% effective in preventing COVID-19
By Julie Steenhuysen and Michael Erman Nov 16 (Reuters) – Moderna Inc said on Monday its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, becoming the second U.S. company in a week to report results that far exceed expectations. Together with Pfizer Inc’s vaccine, also shown to be more than 90% effective, and pending more safety data and regulatory review, the United States could have two vaccines authorized for emergency… Source link
Read More »Stock futures advance after new Moderna data stokes vaccine optimism
Stock futures opened higher Tuesday evening after newly published data from Moderna (MRNA) fueled hopes that a vaccine providing protection against Covid-19 would be developed in the relative near-term. Moderna’s vaccine produced neutralizing antibodies in all 45 patients included in an early-stage human safety trial, according to data published after market close by the peer-reviewed New England Journal of Medicine. The data built on earlier promising, but incomplete, results Moderna had… Source link
Read More »